Connor, Clark & Lunn Investment Management Ltd. Sage Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 65,562 shares of SAGE stock, worth $345,511. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,562

Holding current value

$345,511

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$7.02 - $13.08 $460,245 - $857,550	65,562 New	65,562 $472,000
Q2 2023 Aug 10, 2023	SELL	$40.65 - $59.54 $621,660 - $910,545	-15,293 Reduced 14.08%	93,329 $4.39 Million
Q1 2023 May 09, 2023	SELL	$37.27 - $46.57 $262,492 - $327,992	-7,043 Reduced 6.09%	108,622 $4.56 Million
Q4 2022 Feb 10, 2023	BUY	$32.2 - $43.61 $1.82 Million - $2.46 Million	56,482 Added 95.44%	115,665 $4.41 Million
Q3 2022 Nov 10, 2022	BUY	$32.28 - $43.27 $178,831 - $239,715	5,540 Added 10.33%	59,183 $2.32 Million
Q2 2022 Aug 05, 2022	BUY	$27.52 - $37.99 $306,572 - $423,208	11,140 Added 26.21%	53,643 $1.73 Million
Q1 2022 May 12, 2022	SELL	$30.71 - $45.71 $948,140 - $1.41 Million	-30,874 Reduced 42.08%	42,503 $1.41 Million
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $724,300 - $920,717	19,544 Added 36.3%	73,377 $3.12 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $2.17 Million - $3.09 Million	53,833 New	53,833 $2.39 Million
Q2 2021 Aug 12, 2021	SELL	$54.88 - $79.29 $581,508 - $840,156	-10,596 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $417,117 - $571,271	5,904 Added 125.83%	10,596 $793,000
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $274,059 - $417,869	4,692 New	4,692 $406,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $313M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Sage Therapeutics, Inc. Transaction History